Artificial Intelligence and the Pharmaceutical Supply Chain: A Theoretical Framework for Demand Forecasting, Quality Assurance and the Detection of Substandard and Falsified Medicines in African Markets

Abstract

African pharmaceutical markets suffer at once from stock-outs of essential medicines and from the circulation of substandard and falsified products. Both are supply-chain failures, and artificial intelligence (AI) and related technologies, demand forecasting, track-and-trace, spectroscopic and image-based authentication, are being deployed against them. This theoretical paper develops a framework for the contribution of these technologies to pharmaceutical supply-chain integrity. It draws on supply-chain and operations theory, on the pharmaceutical-regulation and medicine-quality literatures, and on recent research on machine learning for demand forecasting, blockchain-based traceability and AI-enabled detection of falsified medicines. The analysis separates three functions: forecasting, which ensures that the right quantities are in the right places; tracing, which ensures that what moves through the chain is what it claims to be; and testing, which detects substandard product at the point of use. Each faces a distinctive obstacle in fragmented African markets, as forecasting lacks consumption data, tracing requires participation by actors with incentives to remain untraceable, and testing requires devices and skills at the periphery. On this basis the paper advances a set of propositions about the conditions under which each technology improves medicine availability and quality, about the interaction between formal and informal distribution channels, and about the regulatory architecture required, with Nigeria's pharmaceutical market and regulator anchoring the analysis. It concludes that these technologies help only where the institutions to act on their outputs exist, and that building those institutions is the precondition for the technology to matter. It further argues that technology directed at the formal distribution channel is most effective when combined with measures that shift supply from informal to formal channels, where many of the risks of stock-out and of substandard and falsified medicines are concentrated.